Info

PharmAthene, Inc. (PharmAthene), formerly Healthcare Acquisition Corp., is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. The Company has two products under development: Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and Protexia, which mimics a natural bioscavenger, for the treatment or prevention of nerve agent poisoning by organophosphate compounds, which include nerve gases and pesticides. In April 2008, PharmAthene completed the acquisition from Avecia Biologics Limited, Avecia Biologics, Inc., Avecia Biotechnology Inc. and Avecia Limited (collectively, Avecia) of all the assets related to Avecia’s biodefense vaccines business (Avecia Vaccines), which includes a second-generation recombinant protective antigen (rPA) anthrax vaccine, a recombinant dual antigen plague vaccine and a third-generation rPA anthrax vaccine, on April 2, 2008.